ライフサイエンスコーパス: fasting blood glucose

1 cardiovascular risk factors (cholesterol and fasting blood glucose).

2 such as triglycerides, HDL cholesterol, and fasting blood glucose.

3 t diabetes of >/=2 wk duration that measured fasting blood glucose.

4 inal 3 weeks of the diet exhibited decreased fasting blood glucose.

5 d in significantly but only slightly lowered fasting blood glucose (-0.14 mmol/L; 95% CI: -0.24, -0.0

6 emoglobin (HbA1c, -1.3 +/- 1.8%, P < 0.001), fasting blood glucose (-37.8 +/- 70.4 mg/dL, P < 0.001)

7 = 55 (2.9%)), and impaired fasting glucose (fasting blood glucose 5.6-6.9 mmol/L; n = 744 (38.8%)).

8 e had poor metabolic control, with 497 mg/dl fasting blood glucose and 15.6% HbA1c.

9 Lower glycemic index (GI) diets reduced both fasting blood glucose and glycated proteins independentl

10 MTZ reduced fasting blood glucose and HbA(1c) levels in db/db mice,

11 Fasting blood glucose and HbA1c levels, retinopathy, lip

12 Rb1 also significantly decreased fasting blood glucose and improved glucose tolerance, an

13 Gcgr(Hep)(-/-) mice exhibited reductions in fasting blood glucose and improvements in insulin sensit

14 The main outcomes analyzed were fasting blood glucose and insulin as well as fasting tri

15 ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved gl

16 ount of total visceral adipose tissue (VAT), fasting blood glucose and insulin levels, homeostasis mo

17 nificantly associated with liability to T2D, fasting blood glucose and insulin resistance; (v) DNA me

18 Fasting blood glucose and lipid levels, the results of a

19 Fasting blood glucose and lipids did not differ, yet SM2

20 of diabetes, XMetA markedly reduced elevated fasting blood glucose and normalized glucose tolerance.

21 PDX-1(+/-) mice had a normal fasting blood glucose and pancreatic insulin content but

22 The mice maintained a normal level of fasting blood glucose and responded to the diabetogenic

23 atonin (MTNR1B) is associated with increased fasting blood glucose and risk of T2D, but whether sleep

24 N-ethylcarboxamidoadensoine (NECA) increased fasting blood glucose and slowed glucose disposal during

25 ncluding blood pressure, waist to hip ratio, fasting blood glucose and triglyceride levels.

26 valuated for impaired glucose homeostasis by fasting blood glucose and/or oral glucose tolerance test

27 terol, total cholesterol, triglycerides, and fasting blood glucose) and identified several cis-eGenes

28 th CVD risk factors (lipids, blood pressure, fasting blood glucose, and body mass index) in the same

29 eta-cell display improved glucose tolerance, fasting blood glucose, and GSIS, whereas G6PC2 levels ar

30 n hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decre

31 ug/kg) improved glucose tolerance, decreased fasting blood glucose, and increased insulin-stimulated

32 o be significant (P <0.05), for BW, WC, BMI, fasting blood glucose, and IPGTT-AUC.

33 ffects on [(18)F]FDG-PET, fasting C-peptide, fasting blood glucose, and pS6.

34 od samples were assessed for hemoglobin A1c, fasting blood glucose, and serum lipids.

35 or P25-complex tocotrienol) on blood lipids, fasting blood glucose, and the excretion of 8-iso-prosta

36 ting systolic and diastolic blood pressures, fasting blood glucose, and total cholesterol.

37 1, when dosed orally, was found to decrease fasting blood glucose at 30 mg/kg in a streptozotocin-tr

38 All remaining recipients with two fasting blood glucoses between 5.6 and 6.9 mmol/L were i

39 In each of the 3 trials, baseline fasting blood glucose, body mass index, hypertension, an

40 betic mice, Ad-hACE2-eGFP treatment improved fasting blood glucose but had no effect on any of the ot

41 mg/kg/day for 2 weeks significantly reduced fasting blood glucose by 18%, with significant increase

42 receptor modulator, to db/db mice normalizes fasting blood glucose by increasing beta-cell mass and b

43 esults of biochemical parameters showed that fasting blood glucose, C-peptide, fructosamine, triglyce

44 Medical history, a fasting blood glucose, calcineurin inhibitor blood level

45 ciency is associated with elevated levels of fasting blood glucose, circulating insulin, cholesterol

46 G4KO mice exhibited elevated fasting blood glucose compared with C57BL/6J mice.

47 nts exhibited significantly lower random and fasting blood glucose compared with mice transplanted wi

48 In people without diabetes, fasting blood glucose concentration is modestly and non-

49 out a history of diabetes, information about fasting blood glucose concentration or impaired fasting

50 Fasting blood glucose concentration was non-linearly rel

51 -analysis of individual records of diabetes, fasting blood glucose concentration, and other risk fact

52 d its components-abdominal obesity, elevated fasting blood glucose concentration, low high-density li

53 iagnosis of diabetes mellitus rely mainly on fasting blood glucose concentrations and use a lower cut

54 show that acute ethanol exposure also lowers fasting blood glucose concentrations by inhibiting the C

55 Compared with fasting blood glucose concentrations of 3.90-5.59 mmol/L

56 se effects were greater in persons with poor fasting blood glucose control.

57 Body weight and fasting blood glucose did not differ between wild-type a

58 Age, family history, Fasting Blood Glucose, dyslipidaemia, lipid profile, par

59 Body weight, organ mass, fasting blood glucose, energy expenditure, cardiac geome

60 Posttransplant DM was screened for by fasting blood glucoses every 1-3 months.

61 for complex survey design were used in which fasting blood glucose, fasting insulin, and HbA1c were o

62 Fasting blood glucose, fasting insulin, and insulin tole

63 The mice also had elevated fasting blood glucose, fatty liver, and insulin resistan

64 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) l

65 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) l

66 all three genes were associated with either fasting blood glucose (FBG) and/or 2-h blood glucose (BG

67 ) showed significant improvement in both the fasting blood glucose (FBG) concentration (-37.0 mg/dL;

68 Among nondiabetic individuals, higher fasting blood glucose (FBG) independently predicts diabe

69 Elevated fasting blood glucose (FBG) is associated with increased

70 s glycated hemoglobin (A1C) less than 6% and fasting blood glucose (FBG) less than 100 mg/dL off diab

71 Fasting blood glucose (FBG) levels fell from 11.9 +/- 1.

72 We abstracted all outpatient fasting blood glucose (FBG) levels for up to 60 months b

73 mportant common determinant of variations in fasting blood glucose (FBG) levels in humans.

74 iated negatively with Waist hip ratio (WHR), fasting blood glucose (FBG), 2-hour blood glucose after

75 f glucomannan on plasma lipids, body weight, fasting blood glucose (FBG), and blood pressure (BP), bu

76 ween phthalate metabolite concentrations and fasting blood glucose (FBG), homeostasis model assessmen

77 igh-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), hsCRP, TNF-alpha, PAI-1, an

78 ugh this was not associated with a change in fasting blood glucose (FBG), or GSIS from isolated islet

79 a period of 8 weeks posttransplant to assess fasting blood glucose (FBG), serum insulin (SI) levels,

80 response (AIR), disposition index (DI), and fasting blood glucose (FBG)--using generalized estimatin

81 /- SD: GDR 15.8 +/- 2.0 mg. kg(-1). min(-1), fasting blood glucose [FBG] 4.7 +/- 0.3 mmol/l, BMI 26 +

82 lycemic control (random blood glucose [RBG], fasting blood glucose [FBG], and glycated hemoglobin [Hb

83 ght and cardiometabolic risk factor changes (fasting blood glucose [FBG], glycosylated hemoglobin [Hb

84 Associations with fasting blood glucose (FG) and fasting insulin, 2-h post

85 BDNF treatment normalized fasting blood glucose from initially hyperglycemic level

86 assessed with use of measurements of HbA1c, fasting blood glucose, glycemic variability assessed wit

87 35 inches (women) or > or = 40 inches (men); fasting blood glucose > or = 100 mg/dL; serum triglyceri

88 that 4 factors independently predicted NOD: fasting blood glucose >100 mg/dl, fasting triglycerides

89 s were markedly hyperglycemic pretransplant (fasting blood glucose >300 mg/dl).

90 Of the NOD mice, 11 and 70% had diabetes (fasting blood glucose >8.3 mmol/l) at 13 and 18 weeks of

91 use; n = 163 (8.5%)), undiagnosed diabetes (fasting blood glucose >or=7.0 mmol/L without diagnosed d

92 PCSK9 genetic variants with LDL cholesterol, fasting blood glucose, HbA1c, fasting insulin, bodyweigh

93 DL-cholesterol, triglycerides and potassium, fasting blood glucose, heart rate, and bodyweight on dif

94 ed with a higher risk of developing elevated fasting blood glucose (HR = 1.33, 95% CI: 1.14, 1.56).

95 c activator, CDN1163, which markedly lowered fasting blood glucose, improved glucose tolerance, and a

96 f E6 significantly decreased body weight and fasting blood glucose, improved lipid metabolism, and al

97 We found that treatment with ApoA-IV lowered fasting blood glucose in both WT and diabetic KKAy mice

98 Particulate air pollution and fasting blood glucose in nondiabetic individuals: associ

99 -1 receptor antagonist exendin-(9-39) raises fasting blood glucose in normal mice.

100 il, and 20.4% protein, significantly lowered fasting blood glucose in obese, hyperglycemic mice.

101 to examine the effects of exendin-(9-39) on fasting blood glucose in subjects with K(ATP)HI.

102 e we examine the effect of exendin-(9-39) on fasting blood glucose in SUR-1(-/-) mice.

103 mol/l) resulted in a concentration-dependent fasting blood glucose-independent induction of both endo

104 In both lines, fasting blood glucose initially declined equally.

105 Fasting blood glucose, insulin sensitivity, and beta-cel

106 Nat1-deficient mice had elevations in fasting blood glucose, insulin, and triglycerides and de

107 d its effect on glycated hemoglobin (HbA1c), fasting blood glucose, insulin, and triglycerides.The ob

108 IRKO mice had fasting blood glucose, insulin, free fatty acid, and tri

109 rotein-a, high-sensitive C-reactive protein, fasting blood glucose, insulin, interleukin-6 (IL-6), tu

110 All recipients had normal levels of fasting blood glucose, intravenous glucose tolerance, an

111 One means to lower fasting blood glucose is to reduce the glucose output of

112 -wide association study gene associated with fasting blood glucose, is a negative regulator of glucos

113 ulin glargine) with dose titration targeting fasting blood glucose less than 110 mg/dL.

114 ence interval (CI): 1.06, 1.52), an elevated fasting blood glucose level (HR = 1.20, 95% CI: 1.03, 1.

115 -2.2% [CI, -2.9% to -1.4%]) (24 studies) and fasting blood glucose level (net change, -0.12 mmol/L [-

116 Pigs receiving IDN6556 had lower fasting blood glucose level after transplantation and a

117 Fasting blood glucose level increased an average of 0.3

118 s to receive insulin glargine (with a target fasting blood glucose level of </=95 mg per deciliter [5

119 poorly controlled diabetes mellitus, with a fasting blood glucose level of 410 mg/dL (22.8 mmol/L) a

120 d include demographic data, blood pressures, fasting blood glucose level, and lipid profile.

121 rotein), glycated hemoglobin level, and mean fasting blood glucose level.

122 poprotein cholesterol (LDL-cholesterol), and fasting blood glucose level.

123 K-treated diabetic mice displayed normalized fasting blood glucose levels (95 +/- 4.8 mg/dl; P < 0.00

124 Hemoglobin A1c (HbA1c) and fasting blood glucose levels (FBGLs) were recorded.

125 ng depth [PD], marginal bone loss [MBL]) and fasting blood glucose levels (FBGLs) were recorded.

126 days (short term) resulted in a decrease in fasting blood glucose levels (from 173 +/- 11 mg dl-1 on

127 nitored for dietary intake, body weight, and fasting blood glucose levels after islet transplantation

128 Allograft survival was determined by fasting blood glucose levels and flow cytometric techniq

129 ed with 5-thio-glucose was impaired, whereas fasting blood glucose levels and food intake after an ov

130 ved that oral administration of ANC improved fasting blood glucose levels and glucose tolerance in hy

131 The effect of HNP-1 on fasting blood glucose levels and the expression of hepat

132 Fasting blood glucose levels and those after a glucose t

133 Fasting blood glucose levels averaged 12.1 +/- 1.1 (mean

134 Aqp7-/- mice exhibited normal fasting blood glucose levels but elevated blood insulin

135 After 12 weeks, mean (+/-SE) HbA1c and fasting blood glucose levels decreased with active thera

136 In addition, fasting blood glucose levels for DKO mice were significa

137 ur (CDSF) were effective in acutely lowering fasting blood glucose levels in diet induced obese hyper

138 Transplantation normalized fasting blood glucose levels in nine out of nine dogs fo

139 liver was also evident from markedly reduced fasting blood glucose levels in ob/ob-klotho DKO mice, c

140 ion of pure D3S5G dose-dependently decreased fasting blood glucose levels in obese C57BL/6J mice, and

141 found to be more a more sensitive test than fasting blood glucose levels in PTDM, with 10.1% of all

142 Fasting blood glucose levels in SUR-1(-/-) mice treated

143 injection directly into the VMN also lowered fasting blood glucose levels in uncontrolled insulin-def

144 a higher percentage (100% vs. 33.3%) showed fasting blood glucose levels less than 11 mM.

145 In contrast, the lowered fasting blood glucose levels observed in ghrelin recepto

146 provement in glucose tolerance and had lower fasting blood glucose levels than Av3Null-treated mice.

147 Mean fasting blood glucose levels were equivalent between gro

148 Fasting blood glucose levels were measured using a gluco

149 Fasting blood glucose levels were monitored for 14 days.

150 ed diabetic rats revealed the following: (1) fasting blood glucose levels were reduced to normal; (2)

151 Mean fasting blood glucose levels were significantly higher i

152 After cessation of sub-acute dosing, fasting blood glucose levels were significantly lower in

153 Fasting blood glucose levels were similar among age-matc

154 othelium resulted in significantly increased fasting blood glucose levels, a blunted insulin response

155 Cardiovascular disease risk factors, fasting blood glucose levels, and diabetes medication hi

156 the liver augments gluconeogenesis, raising fasting blood glucose levels, and hepatic FoxO6 depletio

157 n receptor null mice and also helps maintain fasting blood glucose levels, ensuring an adequate suppl

158 ignificantly (p < 0.01) decreased random non-fasting blood glucose levels, from 351 +/- 20 mg/dl to a

159 Lower fasting blood glucose levels, higher insulin, and lower

160 Fasting blood glucose levels, medication type and dose,

161 of 1-10), consisting of duration of obesity, fasting blood glucose levels, the presence of high blood

162 mice promoted gluconeogenesis and increased fasting blood glucose levels.

163 th lean and obese mice resulted in decreased fasting blood glucose levels.

164 O1 protein levels in fasted mice, as well as fasting blood glucose levels.

165 dL, untreated blood pressure <120/<80 mm Hg, fasting blood glucose <100 mg/dL, and ideal physical act

166 by using self-administered questionnaires, a fasting blood glucose measurement, a 2-h oral-glucose-to

167 In vivo, transgene induction lowered fasting blood glucose, mimicking EIHI.

168 Diabetes was defined as a fasting blood glucose of 126 mg/dl or more or pharmacolo

169 smetabolism in these patients than levels of fasting blood glucose or glycated hemoglobin.

170 score was associated with 0.46 mg/dL higher fasting blood glucose (p = .0038), and a 1-unit-higher o

171 egative correlation between islet number and fasting blood glucose (P = 0.02).

172 Serum fasting blood glucose, peak amylase, and serial amylase

173 level, homocysteine level, leukocyte count, fasting blood glucose, periodontal disease, ankle-brachi

174 tein, ankle-brachial index, leukocyte count, fasting blood glucose, periodontal disease, carotid inti

175 s on glycemic regulation, including reducing fasting blood glucose, postprandial glucose and insulin

176 Diastolic dysfunction was correlated with fasting blood glucose (r = .69, P < .006) but not with p

177 %), blood pressure (range, 11.9%-16.3%), and fasting blood glucose (range, 31.2%-42.9%) were lower in

178 Fasting blood glucose remained normal in the mice even a

179 Our findings for metabolic syndrome and high fasting blood glucose remained significant for PM2.5 lev

180 tion with AAA mortality (P</=0.007), whereas fasting blood glucose showed no association.

181 factors (blood pressure, total cholesterol, fasting blood glucose, smoking) were defined as poor, in

182 f white adipose tissue, and a slightly lower fasting blood glucose than controls.

183 analyzed the relationship of diabetes and of fasting blood glucose to the level of pulmonary function

184 Weight loss significantly reduced fasting blood glucose, total cholesterol, triglycerides,

185 apoptosis (r = 0.10, P = 0.65), whereas the fasting blood glucose was (r = 0.77, P < 0.001).

186 Fasting blood glucose was 91 +/- 10 mg/dL at baseline fo

187 Fasting blood glucose was increased in high-fat compared

188 Because EGP is a primary determinant of fasting blood glucose, we hypothesize that a protective

189 T2D mice, NR greatly reduced non-fasting and fasting blood glucose, weight gain and hepatic steatosis

190 diagnosis of diabetes and a higher level of fasting blood glucose were associated with lower than pr

191 e systolic and diastolic blood pressures and fasting blood glucose were consistently associated with

192 Blood pressure and fasting blood glucose were not significantly associated

193 hibited enhanced insulin secretion and lower fasting blood glucose within 8 weeks of birth, but reduc

194 fied a quantitative trait locus that affects fasting blood glucose within the Framingham Heart Study